OptiNose Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" OptiNose stock.
View analyst ratings for OptiNose or view top-rated stocks.

Wall Street analysts have given OptiNose a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OptiNose wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

OptiNose is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for OptiNose.

OptiNose, Inc. (NASDAQ:OPTN) released its earnings results on Tuesday, March, 2nd. The company reported ($0.46) EPS for the quarter, meeting the consensus estimate of ($0.46). The company had revenue of $16.35 million for the quarter, compared to analysts' expectations of $18.25 million. OptiNose had a negative trailing twelve-month return on equity of 294.64% and a negative net margin of 230.14%.
View OptiNose's earnings history.

OptiNose's stock was trading at $5.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OPTN stock has decreased by 31.8% and is now trading at $3.45.
View which stocks have been most impacted by COVID-19.

OptiNose issued an update on its FY 2021 Pre-Market earnings guidance on Wednesday, March, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80 million, compared to the consensus revenue estimate of $103.19 million.

2 analysts have issued 1 year target prices for OptiNose's shares. Their forecasts range from $17.00 to $19.00. On average, they anticipate OptiNose's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 421.7% from the stock's current price.
View analysts' price targets for OptiNose or view top-rated stocks among Wall Street analysts.

Some companies that are related to OptiNose include BELLUS Health (BLUSF), Xenon Pharmaceuticals (XENE), Lexicon Pharmaceuticals (LXRX), Karyopharm Therapeutics (KPTI), ZIOPHARM Oncology (ZIOP), Emisphere Technologies (EMIS), Calliditas Therapeutics AB (publ) (CALT), VBI Vaccines (VBIV), Intercept Pharmaceuticals (ICPT), Chimerix (CMRX), Veru (VERU), Chinook Therapeutics (KDNY), Bicycle Therapeutics (BCYC), Kadmon (KDMN) and Gossamer Bio (GOSS).
View all of OPTN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX).

(OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPTN stock can currently be purchased for approximately $3.45.

OptiNose has a market capitalization of $182.66 million and generates $34.63 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis.

OptiNose employs 204 workers across the globe.

The official website for OptiNose is www.optinose.com.

OptiNose is headquartered at 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067.

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]